Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Third Seven Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
Third Seven Capital

Third Seven Capital

Operating

Third Seven Capital LLC: A strategic investment banking firm offering financial advisory and M&A services.

Location
New York City, NY, US
Founded
2011
Firm
Compare
Portfolio
Employees
Website

Third Seven Capital is a boutique investment bank specializing in sourcing premium, off-market deals for disruptive companies. They focus on raising capital for firms in healthcare, technology, and real estate sectors. Their extensive network provides access to exclusive investment opportunities not typically available to the general public.

Notable portfolio companies include Armis Biopharma, Four Springs Capital Trust, and Newlight Technologies. Third Seven Capital offers strategic planning, mergers and acquisitions advisory, capital raising, and valuation services. Their high-touch approach and expertise in sourcing unique deals set them apart in the investment banking landscape.

Third Seven Capital - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments8
Current Portfolio Count8
Total Portfolio Exits0

Top Investment Stages

Seed3 (37.5%)
Series B2 (25.0%)
Series Unknown2 (25.0%)
Series F1 (12.5%)

Stage Mix

Seed 38%Series B 25%Series Unknown 25%Series F 13%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Pangaea logo

Pangaea

Four Springs Capital Trust logo

Four Springs Capital Trust

Newlight Technologies logo

Newlight Technologies

Wunderkind logo

Wunderkind

Ehmetdx logo

Ehmetdx

Fund That Flip logo

Fund That Flip

HFactor logo

HFactor

Armis Biopharma logo

Armis Biopharma

Third Seven Capital - Similar Investment Firms

Thirdbase Capital logo

Thirdbase Capital

thirdbasecap.com

Third Coast Capital logo

Third Coast Capital

thirdcoastca.com

Layer 7 Capital logo

Layer 7 Capital

layer7capital.com

7Thirty logo

7Thirty

7thirtycapital.com

ThirdStream Partners logo

ThirdStream Partners

Three Fish Capital logo

Three Fish Capital

Brookline Capital Markets logo

Brookline Capital Markets

Tercera logo

Tercera

tercera.io

SevenTrainVentures logo

SevenTrainVentures

Third Eye Capital logo

Third Eye Capital

Third Prime logo

Third Prime

thirdprime.vc

Syven Capital logo

Syven Capital

syven.com

Focus Capital Partners logo

Focus Capital Partners

Third Point logo

Third Point

thirdpoint.com

Fifth Third Capital logo

Fifth Third Capital

Third Seven Capital - Classification

NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end
Show 11 more industry codes
NAICS
  • 523100Securities and Commodity Contracts Intermediation and Brokerage
  • 523150Investment Banking and Securities Intermediation
  • 522000Credit Intermediation and Related Activities
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 522100Depository Credit Intermediation
  • 522110Commercial Banking
SIC
  • 6210Security Brokers, Dealers, And Flotation Companies
  • 6211Security Brokers, Dealers, And Flotation Companies
  • 6000Depository Institutions
  • 6200Security And Commodity Brokers, Dealers, Exchanges, And Services
  • 6020Commercial Banks